Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Altimmune (ALT) Amortization of Deferred Charges (2016 - 2025)

Altimmune (ALT) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $192000.0 as the latest value for Q4 2025.

Quarterly Amortization of Deferred Charges changed N/A to $192000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $485611.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $363000.0 for FY2025, N/A changed from the prior year.
Amortization of Deferred Charges for Q4 2025 was $192000.0 at Altimmune, up from $113000.0 in the prior quarter.
The five-year high for Amortization of Deferred Charges was $192000.0 in Q4 2025, with the low at $113000.0 in Q3 2025.